Cargando…
Determination of rivaroxaban in patient’s plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS)
Rivaroxaban is an oral direct factor Xa inhibitor, therapeutically indicated in the treatment of thromboembolic diseases. As other new oral anticoagulants, routine monitoring of rivaroxaban is not necessary, but important in some clinical circumstances. In our study a high-performance liquid chromat...
Autores principales: | Derogis, Priscilla Bento Matos, Sanches, Livia Rentas, de Aranda, Valdir Fernandes, Colombini, Marjorie Paris, Mangueira, Cristóvão Luis Pitangueira, Katz, Marcelo, Faulhaber, Adriana Caschera Leme, Mendes, Claudio Ernesto Albers, Ferreira, Carlos Eduardo dos Santos, França, Carolina Nunes, Guerra, João Carlos de Campos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295670/ https://www.ncbi.nlm.nih.gov/pubmed/28170419 http://dx.doi.org/10.1371/journal.pone.0171272 |
Ejemplares similares
-
Comparison of different laboratory tests in the evaluation of hemorrhagic risk of patients using rivaroxaban in the critical care setting: diagnostic accuracy study
por: Colombini, Marjorie Paris, et al.
Publicado: (2017) -
Diagnostic accuracy of thromboelastometry and its correlation with the HPLC-MS/MS quantification test
por: de Aranda, V.F., et al.
Publicado: (2019) -
Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability
por: Harenberg, Job, et al.
Publicado: (2011) -
Rivaroxaban‐calibrated chromogenic anti‐Xa assay in cirrhosis: Use to rule out disseminated intravascular coagulation
por: Lucas, Fabienne, et al.
Publicado: (2021) -
Rapid Characterization of Triterpene Saponins from Zornia brasiliensis by HPLC-ESI-MS/MS
por: Nascimento, Yuri Mangueira, et al.
Publicado: (2019)